Navigation Links
Insulet Corporation and DexCom Announce Development Agreement
Date:1/7/2008

king statements.

DexCom's Cautionary Statement Regarding Forward Looking Statements

DexCom is a medical device company with a limited operating history. Successful commercialization of the company's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's annual report on Form 10-K for the period ending December 31, 2006, as filed with the Securities and Exchange Commission on February 27, 2007, the company's quarterly report on Form 10-Q for the period ending September 30, 2007, as filed with the Securities and Exchange Commission on October 30, 2007, and its other filings with the Securities and Exchange Commission from time to time. Should one or more of these risks or uncertainties materialize, or should any of the company's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. DexCom undertakes no obligation to publicly update or revise any forward-looking statements.

Contacts for Insulet Corporation

Media:

Mark Sahl, Lazar Partners for Insulet Corporation, Tel. +1-646-871-8485 or +1-609-992-5205

E-mail: msahl@lazarpartners.com

Paul Kidwell, Lazar Partners for Insulet Corporation, Tel. +1-617-296-3854 or +1-617-680-1088

E-mail: pkidwell@lazarpartners.com

Investor Relations:

Stephanie Marks for Insulet Corporation, 877-PODD-IR1 (877-763-3471) ir@insulet.com

Contact for DexCom
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
2. Insulet Corporation Announces Pricing of Secondary Public Offering
3. Insulet Corporation to Report Third Quarter 2007 Financial Results on Wednesday, November 14th
4. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. Brooke Franchise Corporation Announces Selected July Results
7. MedThink Communications Retained by NanoBio Corporation
8. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
11. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Horizon Blue Cross Blue Shield of New Jersey ... again teaming up during The Barclays at The Ridgewood ... Challenge, and Horizon BCBSNJ will be getting spectators into the ... their own. , Horizon BCBSNJ, the official health care sponsor ... donation to the New Jersey Golf Foundation, an organization that ...
(Date:8/19/2014)... NY (PRWEB) August 19, 2014 ... were named the winner of the 2014 Independent ... took home the first place position in “Product ... marketplace specially-formatted eyeliner, which also includes a lash ... black color, plus lash-boosting technology. , ...
(Date:8/19/2014)... August 19, 2014 Following the completion of ... Hyatt Tampa Bay is proud to debut the highly ... project included a full revamp of all public spaces to ... rooms and suites, an all-new dining experience at 1823 Kitchen ... lobby. , With the introduction of 1823 Kitchen and Bar, ...
(Date:8/19/2014)... Philadelphia, PA, August 19, 2014 Warfarin, the ... competition from new options in the anticoagulant drug ... study documents the rapid adoption of these novel ... NOACs accounted for 62% of all new anticoagulant ... drug costs. Findings are published in The ...
(Date:8/19/2014)... Title Boxing Club Cool Springs is now open. ... away prizes – including an entire year's membership. Sweepstakes ... and click on the “Hit It Hard” Sweepstakes. Once ... enters, you will receive an additional chance to win. ... take advantage of the “Pre-Opening Special” which Includes a ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3Health News:Title Boxing Club Cool Springs is Officially Open 2
... CBM ) reports fourth quarter and full year 2008 results ... , Sales increased 0.8% compared ... the impact of foreign currency. Reported sales declined by 6.6% ... Adjusted EBITDA (see attached table) was $10.7 ...
... New Product Development, Marketing and InnovationBEDFORD, Mass., Feb. ... and produced by Insulet Corporation (Nasdaq: ... for the prestigious 2009 Edison Best New Product ... accolades honoring excellence in new product development, marketing, ...
... to better diagnosis, treatment for heart patients , , WEDNESDAY, ... called contrast echocardiography had a significant impact on the ... a new study found. , Echocardiography bounces sound waves ... the moving heart. If that image isn,t clear enough, ...
... than $1000. , ... Eagan, MN (Vocus) February 11, 2009 -- Employees ... United Way of Northeastern Minnesota. A company cookbook was created and ... Iowa. More than 200 cookbooks were sold. , , , ...
... Doctors with Plastic Surgery Services of Fredericksburg ... area to offer LATISSE(TM), the new FDA-approved prescription ... darker, fuller and longer. LATISSE,s maker, Allergan, ... BOTOX(R) and Juvederm(TM). The active ingredient in LATISSE(TM) ...
... doctors at high-volume hospitals do best, study finds , , ... a person surviving a heart attack roughly double ... and facility experienced in the use of angioplasty and ... percutaneous coronary interevention (PCI), which uses angioplasty and a ...
Cached Medicine News:Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 2Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 3Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 4Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 5Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 6Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 7Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 8Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 9Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 10Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 11Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 12Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 13Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 14Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 15Health News:OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM) 2Health News:OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM) 3Health News:Study Brings Value of Echocardiography Into Focus 2Health News:Company Cookbook Proceeds to Benefit United Way of Northeastern Minnesota 2Health News:Long and Lovely Lashes by LATISSE(TM) Now Available Through Plastic Surgery Services of Fredericksburg 2Health News:Experience Brings Better Angioplasty Outcomes 2
(Date:8/18/2014)... , August 19, 2014 Elbit ... EMITF ) announced today that Elbit Medical Technologies ... Company in which it holds approximately 86% of the ... Cell Ltd., in which Elbit Medical holds approximately 30.8% ... majority of Gamida Cell,s shareholders (including Elbit Medical), signed ...
(Date:8/18/2014)... , August 19, 2014 ... cell expansion technologies and therapeutic products, announced today that it ... Pharma AG  ( " Novartis " ... $35 million in Gamida Cell and in return will receive ... The option is exercisable for a limited period of time ...
(Date:8/18/2014)... YORK , Aug. 18, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Biopharmaceutical Markets ... be categorized into three types: chromatography, membranes/filters ... products is increasing and fueling growth of ...
Breaking Medicine Technology:Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... Cempra Pharmaceuticals today announced results from its Phase ... tolerability of oral administration of our fourth generation ... with oral levofloxacin for the treatment of community-acquired ... CEM-101 demonstrated efficacy comparable to levofloxacin and a ...
... Sept. 15, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0240543/Global-Blood-Glucose-Test-Strips-Market-2010-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Test Strips market to grow at a ...
Cached Medicine Technology:Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 2Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 3Global Blood Glucose Test Strips Market 2010-2014 2
... Based on decades of experience, the SSD-1000 ... ultrasound system. It uses our advanced technologies ... experience. Using the same technology as our ... imaging capabilities in a compact and mobile ...
... Using pulsed radiofrequncy current, ... system quickly heats and ablates ... it in minimal time., RF ... in open surgery, percutaneously, or ...
... a biologically based adhesive supplied as ... consisting of a liquid substrate and ... internal bleeding. When combined ... to a prepared wound and tenaciously ...
... (Human) achieves a secure clot, targeted to ... for hemostasis is needed, when control of ... ligature, and cautery, is ineffective or impractical., ... formulation of human Biologically Active Component (BAC) ...
Medicine Products: